Biodesix Targets $20M Series D Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biodesix has closed on the first of two tranches of a financing round targeting $20 million, a company spokesman confirmed today.

The Broomfield, Colo.-based companion diagnostics firm declined to provide details about the tranches, but in a document filed with the US Securities and Exchange Commission, Biodesix said that to date, it has raised $10 million in the round. The offering is in the form of equity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.